Trials / Completed
CompletedNCT03383055
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at various days will be compared.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CMV-MVA Triplex Vaccine | * CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT * TDap administered on Day 56 |
Timeline
- Start date
- 2018-11-16
- Primary completion
- 2021-07-10
- Completion
- 2021-07-10
- First posted
- 2017-12-26
- Last updated
- 2021-08-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03383055. Inclusion in this directory is not an endorsement.